Fibrous dysplasia of bone presenting alongside FGF-23-mediated hypophosphatemia from renal phosphate wasting requires targeted metabolic management to reduce fracture risk and preserve bone integrity in both adults and children.
This protocol applies to patients with fibrous dysplasia of bone who have concurrent FGF-23-mediated hypophosphatemia due to renal phosphate wasting. Hypophosphatemia in this population — across both adults and children — is associated with a higher risk of fractures and must be actively treated. Patients, especially children, should be referred to a metabolic bone specialist with experience in phosphate wasting disorders.
Management involves an active metabolite or analogue of vitamin D in combination with oral phosphate supplementation. The complete regimen — including age-specific considerations for paediatric patients and the full dosing algorithm — is contained in the structured protocol.